September 9 – 10, 2024 | Boston, MA

Major moves in the pharma and biotech partnering are reshaping the landscape. With AbbVie’s acquisition of ImmunoGen leading the charge in 2023, and Merck’s licensing deal with Daiichi reaching unprecedented heights across three ADC programs, the market frenzy surrounding ADCs has never been hotter.

How does one differentiate and obtain assets poised for clinical success in the next wave of deals?

Enter the ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit. This event cuts through the noise of partnership events to gather a targeted critical mass of 100+ ADC companies.

It provides a platform for networking and fast-tracking the search and evaluation of earlier development assets. By significantly improving the alignment, efficiency, and yield of conversations, this summit empowers participants to navigate the complex partnering landscape with confidence.

Beacon is set to join the expert speaker faculty, to deliver an analysis of clinical data and deals & company landscape across the ADCs & Radiopharmaceuticals market; with more data shared than ever before, this is not one to be missed! Find out more about our talk here.